Orphan Exclusivity Dilemma: Without Legislative Fix, US FDA May Seek New Regulation

FDA didn’t get policy rider it wanted which would have reversed the Catalyst court ruling that the agency cannot limit a drug’s orphan exclusivity to its approved indication. One attorney says the clearest path forward is for FDA to issue new rulemaking and face additional litigation.